Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04538352 · ClinicalTrials.gov registry record · Phase 4
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
A Phase 4 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04538352 is a Phase 4 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 60 participants.
The verdict
NCT04538352, a Phase 4 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in diabetes-treatment satisfaction will also be assessed between the two groups.
Interventions
- DRUG Semaglutide
- DRUG Insulin aspart
- DRUG Insulin Degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04538352
The ClinicalTrials.gov registry entry for NCT04538352 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semaglutide is the first listed.
NCT04538352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04538352 about?
NCT04538352 is a clinical study titled "Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D". This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glyc...
What is the current status of trial NCT04538352?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2021-01-18. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT04538352?
The interventions under investigation include: Semaglutide (DRUG), Insulin aspart (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT04538352?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.